Emotional skills boost for cancer survivors: new study shows promise
NCT ID NCT04556344
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether teaching emotional skills (like identifying and managing feelings) can help people who finished cancer treatment. 26 patients with digestive or lung cancer took part. Some received emotional skills training, others did relaxation exercises. The goal was to see if emotional skills improved. This is a small pilot study, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- emotional skills training sessions
- What this could lead to
- If it works, this could point toward a simple, low-cost way to help cancer survivors manage their emotions and improve their quality of life.
- What could go wrong
- This is a very small pilot study with only 26 participants, so results may not apply to everyone. The intervention is brief and may not produce lasting changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
26 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Jan 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient under surveillance after curative or palliative antineoplastic treatment (surgery and/or chemoradiotherapy and/or radiotherapy alone and/or chemotherapy alone) of esogastric or bronchopulmonary cancer, * Patients with a life expectancy estimated by their physician involved in the research to be greater than or equal to six months, * Patient with a ≥ 4 score on the Distress Scale (scale from 0 to 10), * Affiliation to a social security scheme, * Mastery of the French language, * Signing of informed consent to participate in this research. Exclusion Criteria: * Cognitive disorders or unstabilized psychiatric disorders that may impair the ability of reasoning and thinking necessary to complete the questionnaires and attend workshops * Difficulty or deficiency that prevent the patient from a good understanding of the imperatives of the research * Any situation likely to significantly affect emotional competence during the study according to the investigator's judgment (in particular, ongoing psychotherapeutic follow-up)) * Patients under judicial protection (guardianship or curators).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchopulmonary cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Calmette,CHU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which nerve block wins for lung surgery pain?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Could everyday heart drugs shield cancer patients from Radiation's cardiac toll?
- New combo therapy aims to stop liver cancer from coming back
- New hope for advanced colon cancer: which drug combo works best?